- Home
- TYG vs CRMD Comparison
TYG vs CRMD Comparison
Compare TYG & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYG
- CRMD
- Stock Information
- Founded
- TYG 2003
- CRMD 2006
- Country
- TYG United States
- CRMD United States
- Employees
- TYG N/A
- CRMD N/A
- Industry
- TYG Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- TYG Finance
- CRMD Health Care
- Exchange
- TYG Nasdaq
- CRMD Nasdaq
- Market Cap
- TYG 731.0M
- CRMD 871.9M
- IPO Year
- TYG N/A
- CRMD 2010
- Fundamental
- Price
- TYG $42.85
- CRMD $11.62
- Analyst Decision
- TYG
- CRMD Strong Buy
- Analyst Count
- TYG 0
- CRMD 8
- Target Price
- TYG N/A
- CRMD $17.75
- AVG Volume (30 Days)
- TYG 64.7K
- CRMD 2.4M
- Earning Date
- TYG 01-01-0001
- CRMD 11-10-2025
- Dividend Yield
- TYG 10.22%
- CRMD N/A
- EPS Growth
- TYG N/A
- CRMD N/A
- EPS
- TYG 5.19
- CRMD 0.79
- Revenue
- TYG $18,090,640.00
- CRMD $121,484,498.00
- Revenue This Year
- TYG N/A
- CRMD $546.87
- Revenue Next Year
- TYG N/A
- CRMD $51.48
- P/E Ratio
- TYG $8.26
- CRMD $14.68
- Revenue Growth
- TYG 32.84
- CRMD 14970.29
- 52 Week Low
- TYG $33.73
- CRMD $5.60
- 52 Week High
- TYG $48.76
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- TYG 53.44
- CRMD 53.67
- Support Level
- TYG $41.64
- CRMD $10.96
- Resistance Level
- TYG $42.69
- CRMD $11.84
- Average True Range (ATR)
- TYG 0.62
- CRMD 0.61
- MACD
- TYG 0.01
- CRMD 0.11
- Stochastic Oscillator
- TYG 69.64
- CRMD 64.98
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.